AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
AbbVie (ABBV) shares dip as revenue drops 6% from last year
October 27, 2023 9:58 AM EDTAbbVie (NYSE: ABBV) shares dipped at the open Friday despite reporting its latest quarterly earnings that beat consensus expectations.
The pharmaceutical firm reported Q3 EPS of $2.95, $0.08 better than the analyst estimate of $2.87, while revenue for the quarter came in at $13.93 billion versus the consensus estimate of $13.71 billion.
The company's revenue dipped 6% from a year ago. Revenues from its immunology portfolio fell 11.3%, while its oncology segment... More
